glp 1 weight loss drugs Chart: in 8 Americans Now Use GLP-1 for GLP-1 Genetics: How Genes Affect

In March (March 2025), Viking Therapeutics signed a multi-year contract with the CDMO CordenPharma to provide development and manufacturing services for clinical and commercial scale (drug substance and drug product) of VK2735 for both the subcutaneous and oral peptide formulations.

Since then, newer versions like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have emerged with even more powerful effects

2021;4(1):e2033457

The rationale is that weight loss beyond 15% often produces clinically meaningful improvements in joint symptoms, and retatrutide consistently crosses that threshold at moderate doses